Details for Patent: 9,822,157
Which drugs does patent 9,822,157 protect, and when does it expire?
Patent 9,822,157 protects MIMRYLO and is included in one NDA.
This patent has twenty-eight patent family members in twenty countries.
Summary for Patent: 9,822,157
| Title: | Hepcidin analogues and uses thereof |
| Abstract: | The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein. |
| Inventor(s): | Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog |
| Assignee: | Protagonist Therapeutics Inc |
| Application Number: | US14/775,469 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 9,822,157
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-001 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-002 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-003 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-004 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,822,157
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014232954 | ⤷ Start Trial | |||
| Australia | 2018260800 | ⤷ Start Trial | |||
| Canada | 2906830 | ⤷ Start Trial | |||
| China | 105451755 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
